Videos de Experimentos Relacionados
Eficacia de la timostimulina La eficacia de la timostimulina es la eficacia de la timostimulina.
Lancet (London, England)
|January 15, 1994
Resumen
No abstract available in PubMed .
Videos de Conceptos Relacionados
También podría leer
Artículos Relacionados
Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.
Ordenar por
Same author
Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials.
Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same author
Cellular and plasma uptake of parenteral omega-3 rich lipid emulsion fatty acids in patients with advanced pancreatic cancer.
Clinical nutrition (Edinburgh, Scotland)·2013
Same author
Changing trends in the presentation of colorectal liver metastases in a single hepatobiliary tertiary referral centre over fourteen years.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2013
Same author
Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases--safety, pharmacokinetics, and pharmacodynamics.
Cancer prevention research (Philadelphia, Pa.)·2011
Same author
A fuller understanding of pancreatic neuroendocrine tumours combined with aggressive management improves outcome.
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]·2009
Same journal
Assisted dying and the silencing of medicine's next generation.
Lancet (London, England)·2026
Same journal
Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.
Lancet (London, England)·2026
Same journal
Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.
Lancet (London, England)·2026
Same journal
[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.
Lancet (London, England)·2026
Same journal
Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.
Lancet (London, England)·2026